



**SAFETY ASSESSMENTS OF PROTEIN SUPPLEMENT (NRL20195PNV) FOR ACUTE
AND 28 DAYS REPEAT DOSE TOXICITY STUDIES AS PER OECD GUIDELINES**

Priya Khare¹, Dr. Omkar Kulkarni^{2*}, Dr. Anuj Agrawal³, Dr. Gayatri Ganu⁴ and Dr. Sohan Chitlange⁵

¹Manager, R&D (Healthcare), Netsurf Research Labs Pvt. Ltd, Pune, India.

^{2,3}Senior Manager, R&D (Healthcare), Netsurf Research Labs Pvt. Ltd, Pune, India.

⁴Director, Clinical Research, Mprex Healthcare, 414, Nisarg Plaza, Pune, India.

⁵Principal, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research, Pimpri, Pune, India.

*Corresponding Author: Dr. Omkar Kulkarni

Senior Manager, R&D (Healthcare), Netsurf Research Labs Pvt. Ltd, Pune, India.

Article Received on 12/09/2020

Article Revised on 02/10/2020

Article Accepted on 22/10/2020

ABSTRACT

In the present study, we investigated the toxicity of a supplementary protein with micronutrient fortification in mice for determination of LD₅₀ through the acute toxicity study. LD₅₀ values, obtained by single doses were more than 5000 mg/kg body weight. 28 days repeat dose toxicity was studied in rats treated daily with an oral dose of 1000 mg/kg body wt. for 28 days. Hematological and biochemical analyses were carried out together with histological analyses of the liver, heart, kidney and lung tissues etc. As a result, we observed no mortality and non-significant changes in the biological and hematological parameters in rodents after 28 days of daily dosing, it may be concluded that the NRL20195PNV does not appear to have significant toxicity. The histopathological investigations revealed normal articulate and organ weight of vital tissues with no signs of toxicity. Based on the findings of this study, the no observed adverse effect level (NOAEL) of NRL20195PNV in mice, following oral administration for 28 days was found to be 1000 mg/kg body weight.

KEY WORDS: Repeat dose toxicity, histopathology, acute toxicity, nutraceuticals.

INTRODUCTION

Guidelines for dietary protein intake should consider much digestion friendly, good at assimilation protein supplement contenders.^[1] There is great need of research on dietary supplement over their toxicity and efficacy in the selected population.^[2] Dietary protein ingestion is beneficial to support good health, promote recovery from illness, and maintain functionality in adults.^[3] The need for dietary protein supplementation is in part because of a declining anabolic response to protein intake in people; to offset inflammatory and catabolic conditions associated with chronic and acute diseases.^[4]

Acute toxicity studies are designed to measure the short-term adverse effects of a drug when administered in a single or multiple doses during a period of 24 h. Results of acute toxicity studies provide, evidence of appropriate dose range for multiple dose studies, gross mortality evidences, the potential for acute toxicity in humans and evidences for estimation of safe acute doses for humans.^[5-6]

The testing guidelines OECD No. 407, depicts as 28 days repeat dose toxicity or sub-acute systemic toxicity for

which exposure with test drug is continued till 28 days on daily basis. During this type of study, data about observed effects, mortality, body weight, food/water consumption, physical examinations, hematology, blood chemistry, urinalysis, organ weights, gross pathology, and histopathology are collected and analyzed.^[5,7]

By considering need to assess safety of the protein supplement, in this present study, acute and 28 days repeat dose safety assessment of the NRL20195PNV is performed and reported in mice.

MATERIALS AND METHODS

Test material

NRL20195PNV is a protein supplement with micro fortification in a powdered form and intended for human use to promote health and wellbeing.

Key ingredients of the formulation are Milk Solids, Protein blend (Whey Protein Concentrate, Soy protein isolate, Rice protein isolate, Pea protein isolate), DHA (omega 3-Algal source), Aloe vera extract, Ashwagandha extract, Minerals (Calcium phosphate tribasic, potassium citrate, sodium citrate, magnesium sulphate, ferric diphosphate, zinc sulphate, manganese

sulphate, copper sulphate, sodium selenite), Vitamins (ascorbic acid, vitamin E, nicotinamide, calcium-D-pantothenate, pyridoxine hydrochloride, thiamine mononitrate, riboflavin, retinyl acetate, folic acid, D-biotin, phylloquinone, Vitamin D2 ergocalciferol, cyanocobalamin).

Acute Toxicity Study in Mice

The study was conducted in compliance with the OECD Guidelines for Testing of Chemicals (No. 423, Section 4: Health Effects) on conduct of "Acute Oral Toxicity -

Acute Toxic Class Method" (Adopted: 17th December 2001).

28 days repeat dose toxicity study in Mice

The study was conducted as per OECD guideline no. 407, adopted on 3 October 2008.

Husbandry

Following conditions were maintained during husbandry of rodents.

Table 1: Condition maintenance required during Toxicity study.

SN	Parameters	Maintenance
1	Environmental conditions	Air conditioned rooms with 10 - 15 air changes per hour, temperature between 21±2 °C, relative humidity 55 ±5 % and illumination cycle set to 12 hours artificial fluorescent light and 12 hours dark.
2	Accommodation	Individually housed in polypropylene cages with stainless steel grill top, facilities for food and water bottle, and bedding of clean paddy husk.
3	Diet	Pelleted standard rat and mice feed was provided ad libitum
4	Water	Potable water passed through reverse osmosis filtration system and exposed to U.V. ray was provided ad libitum in glass bottles with stainless steel sipper tubes.

Table 2: Details of animals.

1	Species	MICE. Rationale - The guideline followed for this test has preferred mice among the species of rodents.
2	Strain	Swiss albino. The strain was selected due to its availability in requisite numbers, and also the availability of historical background data on its characteristics.
3	Number of animals per dose group	Five males and Five females. Additional satellite groups of Five mice of both sex to be used for assessment of reversibility / delayed toxicity.

Dose Preparation

The test article NRL20195PNV was suspended in Distilled water to obtain desired concentration mg/ml just before dosing every day.

Dose Levels & Justification for acute toxicity study

A starting dose level of 2000 mg/kg body weight was selected from one of the four fixed levels (5, 50, 300 and 2000 mg/kg) based on the available historical toxicity data of the ingredients of NRL20195PNV. Food was withheld for overnight prior to administration of the test article. However, mice had an access to water ad libitum. The toxicity of the test article following oral gavage was assessed by stepwise manner. Three female mice were used per step. The mice were observed for incidence of mortality after 24 hrs. & signs of intoxication for 14 days after the administration of test article. Further, the test was repeated on three more female mice at the same dose level and observed for 14 days.^[8-10]

Selection of Dose Levels for 28 days repeat dose toxicity study

Dose levels selected for this study were based upon the results and findings of dose range finding study. The highest dose chosen for the study was 1000 mg/kg body weight in mice. As per OECD – 407, generally, at least

three test groups and a control group should be used, but if from assessment of other data, no toxic effects would be expected at a dose of 1000mg/kg bw/d, a limit test may be performed and a dose of NRL20195PNV being 1000 mg/kg bw/d could be used to assess safety and toxicity profile for 28 days.

Study Design for 28 days repeat dose toxicity study

Groups of Five male and Five female mice were administered NRL20195PNV by oral gavage daily at the doses of 1000 mg/kg body weight for 28 days and were sacrificed on day 28 to evaluate its toxicity. Concurrent control group receiving the vehicle was also maintained. Additionally, satellite groups of five mice per sex receiving test article at 1000 mg/kg level were further observed for a period of 14 days after 28 days for assessment of reversibility, persistence or delayed occurrence of toxicity.

Administration of Test Article

The animals were dosed by oral gavage at approximately the same time each day where possible, using a graduated syringe and a stainless steel intubation needle (16G). The dosage volume administered to individual mice was adjusted according to its most recently recorded body weight. The control group mice received

the vehicle (Distilled water) only, by oral gavage at the same dosage volume of 10ml/kg body weight. Treatment in this manner was continued once a day, seven days a week, for a total period of 28 days.

The observations like Mortality, Clinical Signs and examinations, Body weights and Food Consumption were made during the course of treatment period i.e. 28 days. Mice belonging to the satellite group were further observed for a post-treatment period of 14 days to permit evaluation of the persistence or reversibility of any toxic effects, or the occurrence of delayed toxicity.

Clinical pathology

Blood samples were withdrawn on the day of termination of the study, under carbon dioxide anesthesia, from the retro-orbital plexus of all the male and female mice of the test and control group. The samples were collected in tubes containing Heparin (for clinical chemistry) and K-EDTA (for hematology) as an anticoagulant. Food was removed overnight from animals to be sampled for laboratory investigations. Blood smears were also made on glass slides. Clinical chemistry samples were centrifuged at a speed of 3000 rpm for 5 minutes.

Hematology, urinalysis and clinical chemistry

The Hematology estimations and serum chemistry parameters, with their units of measurement were analyzed and provided in observations. Urinalysis was performed on all animals. Urine samples were collected using a battery of specially designed stainless steel urine collection cages. Each Mouse was housed in this cage. Urine samples were collected over a period of 3 hours. Food and water was not offered during this period.

Necropsy examination

On completion of 28 days of treatment, all surviving mice were sacrificed by exsanguinations under carbon dioxide anesthesia and were subjected to complete necropsy. The necropsy performed at termination of the treatment was staggered and conducted on days 28. All the tissues as per OECD 407 guidelines, from all animals, were preserved, in 10% neutral buffered formalin. In addition, samples of any macroscopically abnormal tissues were routinely preserved, along with samples of adjacent tissue where appropriate.

Organ weights

Following organs, from all animals killed at the scheduled sacrifices, were dissected free of fat and weighed wet as soon as possible to avoid drying.

Statistical Analysis

The data evaluated by One-Way ANOVA (Dunett's test) and Student's t test using graph pad prism at the level of significance from the control mean ranges at $p < 0.05$.^[11-13]

RESULT AND DISCUSSION

Acute Toxicity Study in Mice

Survival and clinical signs

There was no incidence of treatment related mortality among the female mice exposed to NRL20195PNV at and up to the dose of 2000 mg/kg body weight. Treatment of mice with NRL20195PNV at and up to the dose of 2000 mg/kg did not induce any remarkable abnormal clinical signs.

Body weights

Test product did not induce any remarkable and significant alteration in the group mean body weights of the female mice treated at and up to the dose of 2000 mg/kg.

Food consumption

The values of average daily food consumption by female mice exposed to NRL20195PNV at and up to the dose of 2000 mg/kg were found to be normal.

Ophthalmoscopy

No abnormal findings in cornea, the conjunctivae, the sclera, the iris and fundus were observed.

Necropsy

All animals were subjected to gross necropsy. It is observed that there is no gross pathological findings were encountered in any of the organs.^[8-10]

28 days repeat dosetoxicity study in Mice:

Mortality

There was no incidence of mice exposed mortality among the male and female to the test article (at dose of 1000 mg/kg body wt.) and control group.

Clinical Signs

Treatment of mice with NRL20195PNV at the dose of 1000 mg/kg and concurrent control group did not induce any remarkable abnormal clinical signs in either sex. All these signs were noted only during treatment period. In view of comparable incidence of this finding in these groups, it was considered as incidental in nature.

Body Weights

NRL20195PNV did not induce any remarkable and significant alteration in the body weights of the male and female mice treated at the dose of 1000 mg/kg body weight. Control group also did not induce any remarkable and significant alteration in the body weights of the male and female mice treated at the dose of 1000 mg/kg body weight (Table 3).

Table 3: Average of body weight for test and control group.

SN	Test	Avg % Gain
1	Female	14.37
2	Male	12.92
SN	Control	Avg % Gain
1	Female	8.39
2	Male	8.55

Food Consumption

The value of average daily food consumption by male and female mice exposed to NRL20195PNV at the dose of 1000 mg/kg body weight was found to be comparable to those of the control group over the period of 28 days. Food consumption by NRL20195PNV treated group at 1000 mg/kg of satellite group was comparable with that of control mice. After cessation of treatment, during the recovery period too, the values of daily food intake by the intermediate dose group mice were found to be gradually increasing as during the treatment.

Organ Weights

The groups mean values of absolute and relative weights of kidneys; liver, adrenals, testes/ovaries, spleen, brain,

epididymis/uterus, thymus and hearts of male and female mice treated by NRL20195PNV at 1000 mg/kg were found to be comparable with control group mice at termination of the treatment.

Hematology

The group mean values of hematological parameters viz. hemoglobin (Hb), hematocrit (PCV) and total erythrocyte counts (RBC), total leucocyte count (WBC), differential leucocyte counts (DLC), platelet count, of male and female mice, exposed to NRL20195PNV (at the level of 1000 mg/kg) and control group did not reveal any treatment effect during and at termination of the study (Table 4).

Table 4: Average of Animal Hematology Parameters for test and control group.

Test Group						
	Total Leukocyte Count (X 10 ³ /μL)	RBC Count (X 10 ⁶ /μL)	Hemoglobin (Hb) (g/dL)	Hematocrit (%)	MCV (fl)	MCH (pg)
AVG	1.36	5.96	11.56	33.62	53.34	21.61
SD	0.40	0.86	0.72	1.88	6.24	2.84
	Total WBC count (per cu.mm)	Neutrophils (%)	Lymphocytes (%)	Eosinophils (%)	Monocytes (%)	Platelet Count (X 10 ³ /μL)
AVG	3700	29.9	67.7	3.05	1.12	493.80
SD	579.66	4.46	9.02	0.72	0.27	156.12
Control Group						
	Total Leukocyte Count (X 10 ³ /μL)	RBC Count (X 10 ⁶ /μL)	Hemoglobin (Hb) (g/dL)	Hematocrit (%)	MCV (fl)	MCH (pg)
AVG	1.67	6.43	11.73	33.14	52.09	19.24
SD	0.52	0.88	0.70	4.16	1.18	3.82
	Total WBC count (per cu.mm)	Neutrophils (%)	Lymphocytes (%)	Eosinophils (%)	Monocytes (%)	Platelet Count (X 10 ³ /μL)
AVG	3821.00	31.10	69.00	3.65	1.30	462.40
SD	580.54	4.18	8.56	0.59	0.28	224.10

Biochemistry

Treatment of male and female mice with NRL20195PNV at the dose of 1000 mg/kg did not exhibit any remarkable treatment effect, on their serum biochemistry parameters. As far as the hematological and biochemical parameters are concerned, no index of significant alteration in

relation to control appeared, after 28 days of treatment in both male and female mice at 1000 mg/kg body weight groups. All values found for these parameters were comparable with the existing control groups (Table 5).^[11-13]

Table 5: Average of Biochemical Parameters for test and control group.

Parameter/ Groups	K (Potassium) mmol/l	Na (Sodium) mmol/l	Glucose Mg/dl	Total Cholesterol Mg/dl	Urea Mg/dl	Creatinine Mg/dl	Total pro g/dl	Alb g/dl	ALT IU/L	AST IU/L
TEST GROUP (FEMALE)										
AVG	5.0	135.4	128.0	56.0	13.5	0.7	72.2	33.7	40.6	160.0
SD	0.5	3.0	7.8	11.2	1.1	0.1	4.9	3.0	6.4	14.3
TEST GROUP (MALE)										
AVG	4.58	135.93	139.00	56.73	13.52	0.68	72.70	34.55	40.07	167.14
SD	1.22	3.00	26.07	13.84	1.13	0.09	3.66	2.67	5.84	9.29
CONTROL GROUP (FEMALE)										
AVG	5.0	136.4	129.0	56.0	13.6	0.7	71.7	34.1	41.5	153.6
SD	0.6	2.9	17.9	11.7	1.0	0.1	4.4	3.1	6.7	18.0
CONTROL GROUP (MALE)										
AVG	4.78	134.92	131.40	55.31	13.70	0.74	72.47	36.33	40.57	159.49
SD	0.64	4.07	18.30	16.23	0.89	0.11	3.51	3.11	7.40	13.48

Urinalysis

Treatment of male and female mice with NRL20195PNV (at the dose of 1000 mg/kg) for 28 days and control group did not exhibit any remarkable treatment effect on their urinalysis parameters. The qualitative parameters of urine evaluated for all mice in this study and the microscopic examination of their urine sediment did not reveal any remarkable and treatment related alterations.

Necropsy

NRL20195PNV did not induce any remarkable and treatment related gross pathological alterations in any of the organs / tissues of treated mice at the level of 1000

mg/kg and that of satellite group (1000mg/kg body weight) at day 28.

Histopathology

All the microscopic changes noticed in this study appeared to be incidental, as their frequency and severity remained identical for the control and the treated animals at 1000 mg/kg and N NRL20195PNV treatment at the dose level of 1000 mg/kg body weight. There was no difference in histopathological effects in mice under the said experimental conditions in both groups after 28 days of treatment (fig.1).^[14-16]




Figure 1: Histopathology of vital organs of Test and Control Group.

CONCLUSION

Based on the findings of the study and according to the "Globally Harmonized System (GHS) for classification of chemicals which cause acute toxicity, OECD series on testing and assessment, Number 33; Harmonized Integrated Classification System for Human Health and Environmental Hazards of Chemical Substances and Mixtures [ENV/JM/MONO (2001) 6]", the test article NRL20195PNV has to be classified as GHS Category Unclassified for the obligatory labeling requirement for oral toxicity. This category indicates that following acute oral exposure of NRL20195PNV in female mice; the LD₅₀ cut-off value is more than 5000 mg/kg body weight.

Results of the 28 days repeat dose toxicity indicated that the NRL20195PNV had no adverse effect on general health, growth, behavioral, neurological, hematological, clinical chemistry and urinalysis parameters, organ weights and gross of the tissues/organs of the mice

treated at the dose level of 1000 mg/kg body weight. Based on the findings of this study, the no observed adverse effect level (NOAEL) of NRL20195PNV in mice, following oral administration for 28 days was found to be 1000 mg/kg body weight.

REFERENCES

1. World Health Organization, United Nations University. Protein and amino acid requirements in human nutrition. World Health Organization, 2007; 15.
2. Gaffney-Stomberg E, Insogna KL, Rodriguez NR, Kerstetter JE. Increasing dietary protein requirements in elderly people for optimal muscle and bone health. *Journal of the American Geriatrics Society*, 2009; 57(6): 1073-9.
3. Lupton JR, Brooks JA, Butte NF, Caballero B, Flatt JP, Fried SK. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol,

- protein, and amino acids. National Academy Press: Washington, DC, USA, 2002; 5: 589-768.
4. Kurpad AV, Vaz M. Protein and amino acid requirements in the elderly. *European journal of clinical nutrition*, 2000; 54(3): 131-42.
 5. Prabu SL, Thirumurugan R, Suriyaprakash TN. The role of the drug discovery, clinical, and regulatory affairs teams in turning a potent agent into a registered product.
 6. Chen Y, Chen S, Song C, Yin Z, Chen Z, Jia R, Liang X, Li L, Zou Y, He C, Ye G. Acute and subchronic toxicity as well as evaluation of safety pharmacology of traditional Chinese medicine "Huhezi". *International journal of clinical and experimental medicine*, 2015; 8(8): 14553.
 7. Yu B, Chen X, Jiang L, Shang Y, Song X, Zhou S, Xu J, Yu J, Fu Q, Peng S, Liu S. Acute and subchronic toxicity and the evaluation of safety pharmacology of Chinese herbal compound preparation " Shikuqin". *Pakistan journal of pharmaceutical sciences*, 2018; 31.
 8. Badary OA, Al-Shabanah OA, Nagi MN, Al-Bekairi AM, Elmazar M. Acute and subchronic toxicity of thymoquinone in mice. *Drug Development Research*, 1998; 44(2-3): 56-61.
 9. Patel C, Dadhaniya P, Hingorani L, Soni MG. Safety assessment of pomegranate fruit extract: acute and subchronic toxicity studies. *Food and Chemical Toxicology*, 2008; 46(8): 2728-35.
 10. Goldsmith LA. Acute and subchronic toxicity of sucralose. *Food and chemical toxicology*, 2000; 38: 53-69.
 11. Yuet Ping K, Darah I, Chen Y, Sreeramanan S, Sasidharan S. Acute and subchronic toxicity study of *Euphorbia hirta* L. methanol extract in rats. *BioMed research international*, 2013; 2013: 1-8.
 12. Narasimhamurthy K, Viswanatha S, Ramesh BS. Acute and subchronic toxicity assessment of debitterized fenugreek powder in the mouse and rat. *Food and chemical toxicology*, 1999; 37(8): 831-8.
 13. Yuan G, Dai S, Yin Z, Lu H, Jia R, Xu J, Song X, Li L, Shu Y, Zhao X. Toxicological assessment of combined lead and cadmium: acute and sub-chronic toxicity study in rats. *Food and chemical toxicology*, 2014; 65: 260-8.
 14. Kennedy GL. Acute and subchronic toxicity of dimethylformamide and dimethylacetamide following various routes of administration. *Drug and chemical toxicology*, 1986; 9(2): 147-70.
 15. Tyler TR. Acute and subchronic toxicity of ethylene glycol monobutyl ether. *Environmental health perspectives*, 1984; 57: 185-91.
 16. Korani M, Rezayat SM, Gilani K, Bidgoli SA, Adeli S. Acute and subchronic dermal toxicity of nanosilver in guinea pig. *International journal of nanomedicine*, 2011; 6: 855.